Weaver Consulting Group Brainstorm Cell Therapeutics Inc. Transaction History

Weaver Consulting Group

  • $253 Million
  • Q1 2024

A detailed history of Weaver Consulting Group transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Weaver Consulting Group holds 199,356 shares of BCLI stock, worth $77,748. This represents 0.04% of its overall portfolio holdings.

Number of Shares
199,356
Previous 10,000 1893.56%
Holding current value
$77,748
Previous $2,000 5450.0%
% of portfolio
0.04%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 22, 2024
BUY
$0.15 - $0.4 $15,000 - $40,000
100,000 Added 100.65%
199,356 $53,000
Q3 2023

Oct 13, 2023
BUY
$0.2 - $2.08 $6,928 - $72,057
34,643 Added 53.53%
99,356 $19,000
Q2 2023

Jul 19, 2023
BUY
$2.0 - $3.2 $2,000 - $3,200
1,000 Added 1.57%
64,713 $133,000
Q1 2023

Apr 11, 2023
SELL
$1.43 - $3.3 $3,194 - $7,372
-2,234 Reduced 3.39%
63,713 $210,000
Q4 2022

Jan 09, 2023
SELL
$1.37 - $3.39 $38,394 - $95,004
-28,025 Reduced 29.82%
65,947 $0
Q3 2022

Oct 04, 2022
SELL
$2.55 - $4.3 $27,236 - $45,928
-10,681 Reduced 10.21%
93,972 $415,000
Q2 2022

Jul 20, 2022
SELL
$2.71 - $3.6 $68,690 - $91,249
-25,347 Reduced 19.5%
104,653 $289,000
Q1 2022

May 06, 2022
SELL
$2.92 - $4.19 $74,460 - $106,845
-25,500 Reduced 16.4%
130,000 $437,000
Q4 2021

Feb 01, 2022
BUY
$2.81 - $4.23 $292,240 - $439,920
104,000 Added 201.94%
155,500 $622,000
Q3 2021

Oct 28, 2021
BUY
$3.14 - $4.09 $8,223 - $10,711
2,619 Added 5.36%
51,500 $170,000
Q2 2021

Jul 06, 2021
SELL
$3.01 - $4.01 $3,368 - $4,487
-1,119 Reduced 2.24%
48,881 $186,000
Q1 2021

Apr 07, 2021
BUY
$3.46 - $7.88 $173,000 - $394,000
50,000 New
50,000 $192,000

Others Institutions Holding BCLI

# of Institutions
52
Shares Held
4.09M
Call Options Held
63.2K
Put Options Held
800
View Full List

About BRAINSTORM CELL THERAPEUTICS INC.

BCLI Quotes by TradingView
  • Ticker BCLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,486,200
  • Market Cap $14.2M
  • Description
  • Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...
More about BCLI
Track This Portfolio

Track Weaver Consulting Group Portfolio

Follow Weaver Consulting Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Weaver Consulting Group, based on Form 13F filings with the SEC.

News

Stay updated on Weaver Consulting Group with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email